Main Article Content
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our edition uses the copyright terms of Creative Commons for open access journals.
Authors, who are published in this journal, agree with the following terms:
- The authors retain rights for authorship of their article and grant to the edition the right of first publication of the article on a Creative Commons Attribution 4.0 International License, which allows others to freely distribute the published article, with the obligatory reference to the authors of original works and original publication in this journal.
- Directing the article for the publication to the editorial board (publisher), the author agrees with transmitting of rights for the protection and using the article, including parts of the article, which are protected by the copyrights, such as the author’s photo, pictures, charts, tables, etc., including the reproduction in the media and the Internet; for distributing; for the translation of the manuscript in all languages; for export and import of the publications copies of the writers’ article to spread, bringing to the general information.
- The rights mentioned above authors transfer to the edition (publisher) for the unlimited period of validity and on the territory of all countries of the world.
- The authors guarantee that they have exclusive rights for using of the article, which they have sent to the edition (publisher). The edition (the publisher) is not responsible for the violation of given guarantees by the authors to the third parties.
- The authors have the right to conclude separate supplement agreements that relate to non-exclusive distribution of their article in the form in which it had been published in the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.
- The policy of the journal permits and encourages the publication of the article in the Internet (in institutional repository or on a personal website) by the authors, because it contributes to productive scientific discussion and a positive effect on efficiency and dynamics of the citation of the article.
- The rights to the article are deemed transferred by the authors to the edition (the publisher) since the moment of the publication of the article in the printed or electronic version of journal.
Tkachenko EI, Uspenskii YP, Pakhomova IG, Baryshnikova NV. Gastroesophageal reflux disease: a new solution to an old problem. Novosti Meditsiny i Farmatsii. 2010;5(311). Available from: http://www.mif-ua.com/archive/article/11809
Yuan JQ, Tsoi KK, Yang M, et al. Systematic review with network meta-analysis: comparative effectiveness and safety of strategies for preventing NSAID-associated gastrointestinal toxicity. Aliment Pharmacol Ther. 2016;43(12):1262-75. doi: 10.1111/apt.13642.
Scarpignato C, Gatta L, Zullo A, et al. Effective and safe proton pump inhibitor therapy in acid-related diseases – A position paper addressing benefits and potential harms of acid suppression. BMC Med. 2016;14(1):179. doi:10.1186/s12916-016-0718-z.
Freedberg DE, Kim LS, Yang YX. The Risks and Beneﬁts of Long-term Use of Proton Pump Inhibitors: Expert Review and Best Practice Advice From the American Gastroenterological Association. Gastroenterology. 2017 Mar;152(4):706-715. doi: 10.1053/j.gastro.2017.01.031.
Ivanov DD. Chronic kidney disease. Novosti Meditsiny i Farmatsii. 2010;7(320). Available from: http://www.mif-ua.com/archive/article/12230
Akter S, Hassan MR, Shahriar M, Akter N, Md. G. Abbas G, et al. Cognitive impact after short-term exposure to different proton pump inhibitors: assessment using CANTAB software. Alzheimers Res Ther. 2015; 7: 79. doi: 10.1186/s13195–015–0164–8.
Gomm W, von Holt K, Thome F, et al. Association of Proton Pump Inhibitors With Risk of Dementia: A Pharmacoepidemiological Claims Data Analysis. JAMA Neurol 2016; 73:410-6. doi: 10.1001/jamaneurol.2015.4791.
Targownik LE, Leslie WD, Davison KS, et al. The relationship between proton pump inhibitor use and longitudinal change in bone mineral density: a population-based study [corrected] from the Canadian Multicentre Osteoporosis Study (CaMos). Am J Gastroenterol. 2012;107:1361-9. doi: 10.1038/ajg.2012.200.
Targownik L, Luo Y, Goertzen A, et al. Long-Term Proton Pump Inhibitor Use Is Not Associated With Changes in Bone Strength and Structure. Am J Gastroenterol. 2017;112:95-101. doi:10.1038/ajg.2016.481.
Ghebremariam YT, LePendu P, Lee JC, et al. Unexpected effect of proton pump inhibitors: elevation of the cardiovascular risk factor asymmetric dimethylarginine. Circulation. 2013;128:845-53. doi: 10.1161/CIRCULATIONAHA.113.003602.
Shah NH, LePendu P, Bauer-Mehren A, et al. Proton Pump Inhibitor Usage and the Risk of Myocardial Infarction in the General Population. PLoS One. 2015 Jun 10;10(6):e0124653. doi: 10.1371/journal.pone.0124653. eCollection 2015.
Bavishi C, Dupont HL. Systematic review: the use of proton pump inhibitors and increased susceptibility to enteric infection. Aliment Pharmacol Ther. 2011 Dec;34(11-12):1269-81. doi: 10.1111/j.1365-2036.2011.04874.x.
Brophy S, Jones KH, Rahman MA, et al. Incidence of Campylobacter and Salmonella infections following ﬁrst prescription for PPI: a cohort study using routine data. Am J Gastroenterol. 2013 Jul;108(7):1094-100. doi: 10.1038/ajg.2013.30.
Xu HB, Wang HD, Li CH, et al. Proton pump inhibitor use and risk of spontaneous bacterial peritonitis in cirrhotic patients: a systematic review and meta-analysis. Genet Mol Res. 2015 Jul 6;14(3):7490-501. doi: 10.4238/2015.July.3.25.
Freedberg DE, Toussaint NC, Chen SP, et al. Proton Pump Inhibitors Alter Specific Taxa in the Human Gastrointestinal Microbiome: A Crossover Trial. Gastroenterology. 2015 Oct;149(4):883-5.e9. doi: 10.1053/j.gastro.2015.06.043.
Furuya-Kanamori L, Stone JC, Clark J, et al. Comorbidities, exposure to medications, and the risk of community-acquired Clostridium difficile infection: a systematic review and meta-analysis. Infect Control Hosp Epidemiol. 2015 Feb;36(2):132-41. doi: 10.1017/ice.2014.39.
Dubberke ER, Reske KA, Yan Y, et al. Clostridium difficile–associated disease in a setting of endemicity: identification of novel risk factors. Clin Infect Dis. 2007 Dec 15;45(12):1543-9. doi: 10.1086/523582.
Freedberg DE, Lamouse-Smith ES, Lightdale JR, et al. Use of Acid Suppression Medication is Associated With Risk for C. difficile Infection in Infants and Children: A Population-based Study. Clin Infect Dis. 2015 Sep 15;61(6):912-7. doi: 10.1093/cid/civ432.
Rosen R, Hu L, Amirault J, et al. 16S community profiling identifies proton pump inhibitor related differences in gastric, lung, and oropharyngeal microﬂora. J Pediatr. 2015 Apr;166(4):917-23. doi: 10.1016/j.jpeds.2014.12.067.
Lambert AA, Lam JO, Paik JJ, et al. Risk of community- acquired pneumonia with outpatient proton-pump in- hibitor therapy: a systematic review and meta-analysis. PLoS One. 2015 Jun 4;10(6):e0128004. doi: 10.1371/journal.pone.0128004. eCollection 2015.
Scheiman JM, Devereaux PJ, Herlitz J, et al. Prevention of peptic ulcers with esomeprazole in patients at risk of ulcer development treated with low-dose acetylsalicylic acid: a randomised, controlled trial (OBERON). Heart. 2011 May;97(10):797-802. doi: 10.1136/hrt.2010.217547.
Estborn L, Joelson S. Frequency and time to onset of community-acquired respiratory tract infections in patients receiving esomeprazole: a retrospective analysis of patient-level data in placebo-controlled studies. Aliment Pharmacol Ther. 2015 Sep;42(5):607-13. doi: 10.1111/apt.13304.
Krag M, Perner A, Wetterslev J, et al. Stress ulcer prophylaxis versus placebo or no prophylaxis in critically ill patients. A systematic review of randomised clinical trials with meta-analysis and trial sequential analysis. Intensive Care Med. 2014 Jan;40(1):11-22. doi: 10.1007/s00134-013-3125-3.
O’Connell MB, Madden DM, Murray AM, et al. Effects of proton pump inhibitors on calcium carbonate absorption in women: a randomized crossover trial. Am J Med. 2005;118:778-81. doi: 10.1016/j.amjmed.2005.02.007.
Serfaty-Lacrosniere C, Wood RJ, Voytko D, et al. Hypochlorhydria from short-term omeprazole treatment does not inhibit intestinal absorption of calcium, phos- phorus, magnesium or zinc from food in humans J Am Coll Nutr. 1995 Aug;14(4):364-8.
Stewart CA, Termanini B, Sutliff VE, et al. Iron absorption in patients with Zollinger-Ellison syndrome treated with long-term gastric acid antisecretory therapy. Aliment Pharmacol Ther. 1998 Jan;12(1):83-98.
Cheungpasitporn W, Thongprayoon C, Kittanamongkolchai W, et al. Proton pump inhibitors linked to hypomagnesemia: a systematic review and meta-analysis of observational studies. Ren Fail. 2015 Aug;37(7):1237-41. doi: 10.3109/0886022X.2015.1057800.
den Elzen WP, Groeneveld Y, de Ruijter W, et al. Long- term use of proton pump inhibitors and vitamin B12 status in elderly individuals. Aliment Pharmacol Ther. 2008 Mar 15;27(6):491-7. doi: 10.1111/j.1365-2036.2008.03601.x.
Garcia Rodriguez LA, Lagergren J, Lindblad M. Gastric acid suppression and risk of oesophageal and gastric adenocarcinoma: a nested case control study in the UK. Gut. 2006;55:1538-44. doi: 10.1136/gut.2005.086579.
Song H, Zhu J, Lu D. Long-term proton pump inhibitor (PPI) use and the development of gastric pre-malignant lesions. Cochrane Database Syst Rev. 2014 Dec 2;(12):CD010623. doi: 10.1002/14651858.CD010623.pub2.
Attwood SE, Ell C, Galmiche JP, et al. Long-term safety of proton pump inhibitor therapy assessed under controlled, randomised clinical trial conditions: data from the SOPRAN and LOTUS studies. Aliment Pharmacol Ther. 2015 Jun;41(11):1162-74. doi: 10.1111/apt.13194.
Robertson DJ, Larsson H, Friis S, et al. Proton pump inhibitor use and risk of colorectal cancer: a population-based, case-control study. Gastroenterology. 2007;133:755-60. doi: 10.1053/j.gastro.2007.06.014.
Smith PM, Kerr GD, Cockel R, et al. A comparison of omeprazole and ranitidine in the prevention of recurrence of benign esophageal stricture. Restore Investigator Group. Gastroenterology. 1994;107:1312-8. PMID: 7926495.
Krol N, Wensing M, Haaijer-Ruskamp F, et al. Patient- directed strategy to reduce prescribing for patients with dyspepsia in general practice: a randomized trial. Aliment Pharmacol Ther. 2004;19: 917-22. DOI: 10.1111/j.1365-2036.2004.01928.x.
Lind T, Havelund T, Lundell L, et al. On demand therapy with omeprazole for the long-term management of patients with heartburn without oesophagitis–a placebo- controlled randomized trial. Aliment Pharmacol Ther. 1999;13:907-14. PMID: 10383525.
Pace F, Tonini M, Pallotta S, et al. Systematic review: maintenance treatment of gastro-oesophageal reﬂux disease with proton pump inhibitors taken ’on-demand’. Aliment Pharmacol Ther. 2007;26:195-204. doi: 10.1111/j.1365-2036.2007.03381.x.
Sarr MG, Hamilton SR, Marrone GC, et al. Barrett’s esophagus: its prevalence and association with adenocarcinoma in patients with symptoms of gastroesophageal reﬂux. Am J Surg. 1985;149:187-93. PMID: 3966636.
Chey WD, Inadomi JM, Booher AM, et al. Primary-care physicians’ perceptions and practices on the management of GERD: results of a national survey. Am J Gastroenterol. 2005;100:1237-42. doi: 10.1111/j.1572-0241.2005.41364.x
Hawkey CJ, Karrasch JA, Szczepanski L, et al. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinﬂammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group. N Engl J Med. 1998;338:727-34. doi: 10.1056/NEJM199803123381105.
Scheiman JM, Yeomans ND, Talley NJ, et al. Prevention of ulcers by esomeprazole in at-risk patients using non-selective NSAIDs and COX-2 inhibitors. Am J Gastroenterol. 2006;101:701-10. doi: 10.1111/j.1572-0241.2006.00499.x.
Chan FK, Wong VW, Suen BY, et al. Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trial. Lancet. 2007 May 12;369(9573):1621-6. doi: 1016/S0140-6736(07)60749-1.
Fass R, Inadomi J, Han C, et al. Maintenance of heartburn relief after step-down from twice-daily proton pump inhibitor to once-daily dexlansoprazole modified release. Clin Gastroenterol Hepatol. 2012 Mar;10(3):247-53. doi: 10.1016/j.cgh.2011.11.021.
Sjöstedt S, Befrits R, Sylvan A, et al. Daily treatment with esomeprazole is superior to that taken on-demand for maintenance of healed erosive oesophagitis. Aliment Pharmacol Ther. 2005;22:183-91. doi: 10.1111/j.1365-2036.2005.02553.x.
Mainie I, Tutuian R, Shay S, et al. Acid and non-acid reﬂux in patients with persistent symptoms despite acid suppressive therapy: a multicentre study using combined ambulatory impedance-pH monitoring. Gut. 2006 Oct;55(10):1398-402. DOI: 10.1136/gut.2005.087668.
Goldenberg JZ, Ma SS, Saxton JD, et al. Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children. Cochrane Database Syst Rev. 2013 May 31;(5):CD006095. doi: 10.1002/14651858.CD006095.pub3.